Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 27, Issue , 2016, Pages v28-v37

  Valle, J W ^a   Borbath, I ^b   Khan, S A ^c   Huguet, F ^d   Gruenberger, T ^e   Arnold, D ^f   On behalf of the ESMO Guidelines Committee, ^g  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d HÔPITAL TENON   (France)

^e KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^f Instituto CUF de Oncologia (ICO)   (Portugal)

^g ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PANITUMUMAB; SORAFENIB;

ADJUVANT THERAPY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; BILIARY TRACT SURGERY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CHOLECYSTECTOMY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FOLLOW UP; GALLBLADDER CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER TRANSPLANTATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

EID: 84995766824     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw324     Document Type: Article

References (45)

1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125.
2. Nakeeb A, Pitt HA, Sohn TA et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463-473; discussion 473-475.
3. Bragazzi MC, Cardinale V, Carpino G et al. Cholangiocarcinoma: epidemiology and risk factors. Transl Gastrointest Cancer 2012; 1: 21-32.
4. Shin HR, Oh JK, Masuyer E et al. Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma - focus on East and South-Eastern Asia. Asian Pac J Cancer Prev 2010; 11: 1159-1166.
5. Patel T. Worldwide trends In mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
6. Khan SA, Emadossadaty S, Ladep NG et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 56: 848-854.
7. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 2006; 26: 1047-1053.
8. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76.
9. Welzel TM, Graubard BI, El-Serag HB et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228.
10. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-184.
11. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314.
12. Kumagai S, Kurumatani N, Arimoto A, Ichihara G. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med 2013; 70: 508-510.
13. Nordenstedt H, Mattsson F, El-Serag H, Lagergren J. Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma. Br J Cancer 2012; 106: 1011-1015.
14. Bertran E, Heise K, Andia ME, Ferreccio C. Gallbladder cancer: incidence and survival in a high-risk area of Chile. Int J Cancer 2010; 127: 2446-2454.
15. Park MJ, Kim YK, Lim S et al. Hilar cholangiocarcinoma: value of adding DW imaging to gadoxetic acid-enhanced MR imaging with MR cholangiopancreatography for preoperative evaluation. Radiology2014; 270: 768-776.
16. Pitman MB, Layfield LJ. Guidelines for pancreaticobiliary cytology from the Papanicolaou Society of Cytopathology: a review. Cancer Cytopathol 2014; 122: 399-411.
17. Razumilava N, Gleeson FC, Gores GJ. Awareness of tract seeding with endoscopic ultrasound tissue acquisition in perihilar cholangiocarcinoma. Am J Gastroenterol 2015; 110: 200.
18. Bosman FT; World Health Organization; International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. Lyon, France: IARC Press 2010.
19. Levy C, Lymp J, Angulo P et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 50: 1734.
20. Nakamura H, Arai Y, Totoki Y et al. Genomic spectra of biliary tract cancer. Nat Genet 2015; 47: 1003-1010.
21. In Edge SB, Byrd DR, Compton CC et al (eds). Cancer Staging Handbook from the AJCC Cancer Staging Manual. New York, NY: Springer 2010; 247-276.
22. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215: 31-38.
23. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51: 237-267.
24. Andrén-Sandberg A. Diagnosis and management of gallbladder polyps. N Am J Med Sci 2012; 4: 203-211.
25. de Jong MC, Nathan H, Sotiropoulos GC et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011; 29: 3140-3145.
26. Matsumoto N, Ebata T, Yokoyama Y et al. Role of anatomical right hepatic trisectionectomy for perihilar cholangiocarcinoma. Br J Surg 2014; 101: 261-268.
27. Dickson PV, Behrman SW. Distal cholangiocarcinoma. Surg Clin North Am 2014; 94: 325-342.
28. Ito H, Ito K, D'Angelica M et al. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg 2011; 254: 320-325.
29. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30: 1934-1940.
30. Ben-Josef E, Guthrie KA, El-Khoueiry AB et al. SWOG S0809: a phase II Intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 2015; 33: 2617-2622.
31. Thet Cho M. Adjuvant gemcitabine plus docetaxel followed by 5FU chemoradiation for patients with resected pancreaticobiliary cancers: a single-institution, phase II study. J Clin Oncol 2014; 32 (Suppl.) : abstr e22243.
32. Phelip JM, Vendrely V, Rostain F et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer 2014; 50: 2975-2982.
33. Fuller CD, Dang ND, Wang SJ et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: initial clinical results. Radiother Oncol 2009; 92: 249-254.
34. Al-Adra DP, Gill RS, Axford SJ et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol 2015; 41: 120-127.
35. Glimelius B, Hoffman K, Sjödén PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
36. Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28: 4581-4586.
37. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
38. Okusaka T, Nakachi K, Fukutomi A et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474.
39. Valle JW, Furuse J, Jitlal M et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014; 25: 391-398.
40. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol 2014; 25: 2328-2338.
41. Gruenberger B, Schueller J, Heubrandtner U et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010; 11: 1142-1148.
42. Malka D, Cervera P, Foulon S et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15: 819-828.
43. Moehler M, Maderer A, Schimanski C et al. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme. Eur J Cancer 2014; 50: 3125-3135.
44. Valle JW, Wasan H, Lopes A et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.Lancet Oncol 2015; 16: 967-978.
45. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.